Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients
- 30 September 1992
- journal article
- review article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 43 (1-3), 155-159
- https://doi.org/10.1016/0960-0760(92)90201-s
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancerBritish Journal of Cancer, 1990
- Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effectsBritish Journal of Cancer, 1989
- Shrinkage of uterine fibroids during therapy with goserelin (Zoladex ): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depotFertility and Sterility, 1987
- Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancerEuropean Journal of Cancer and Clinical Oncology, 1986
- Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinomaBreast Cancer Research and Treatment, 1986
- Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast CancerJournal of Clinical Endocrinology & Metabolism, 1982
- Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivoSteroids, 1981
- Resistance of the Ovary to Blockade of Aromatization with Aminoglutethimide*Journal of Clinical Endocrinology & Metabolism, 1980